When cancer is diagnosed, finding treatment options is the top priority

OncoTarget® Series is our comprehensive genomic profiling solution to identify targeted immunotherapies for advanced cancers– solid tumors or leukemias.

Learn about our newly launched, FDA cleared, 500-gene panel OncoTarget® 500

OncoTarget® Series Test Menu

OncoTarget® 500

FDA cleared gene panel testing

OncoTarget® Myeloid68

An NGS-Based Test For Myeloid Leukemia

OncoTarget® Liquid

Hematology Molecular Panel

Hematology FISH Panel

Immuno Profile Panel

Your confidence is found within OncoTarget’s
multi-technology platform

MSI and single mutations

Sample Collection

Sample Processing

Results

GoPath® Diagnostics Launches FDA-Cleared CGP Test under OncoTarget® 500

#ASCO22 week is here and we are excited to announce the release of our FDA-Cleared CGP Test under OncoTarget® 500.

Visit us in booth #28109 on June 4-6 between 9:00 AM–5:00 PM each day and learn how this CGP solution will help advance cancer treatments by identifying genomic targets for both targeted therapy and immunotherapy.

Stay connected